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Mw-adjuvanted recombinant ha,  
nP Proteins, and M2e Peptide 
combination Vaccine in Mice 
correlates with cellular immune 
response
Nilesh B. Ingle, Rashmi G. Virkar and Vidya A. Arankalle*
Hepatitis Division, National Institute of Virology, Pune, India
We documented earlier that Mw (heat-killed suspension of Mycobacterium indicus pranii) 
adjuvant when used with conserved antigens, nucleoprotein (NP), and ectodomain of 
matrix (M2) protein (M2e) provided complete protection against homologous (clade 2.2) 
virus challenge in mice. The present study extends these observations to inter-clade 
challenge (clade 2.3.2.1) H5N1 virus and attempts to understand preliminary immuno-
logic basis for the observed protection. Female BALB/c mice immunized with a single or 
two doses of vaccine formulations (clade 2.2 antigens) were challenged with 100LD50 
homologous or heterologous (clade 2.3.2.1) virus. To understand the preliminary immu-
nologic mechanism, we studied proportions of selected immune cell types, immune 
response gene expression, and Th1/Th2 cytokines induced by antigen-stimulated 
splenocytes from immunized mice, at different time points. Complete protection was 
conferred by Mw-HA, Mw-HA + NP, and Mw-HA + NP + M2e against homologous 
challenge. The protection correlated with IgG2a antibody titers indicating important role 
of Th1 response. Despite high inter-cladal antigenic differences, complete protection 
against the heterologous strain was achieved with Mw-HA + NP + M2e. Of note, a 
single dose with higher antigen concentrations (50 µg HA + 50 μg NP + 50 μg M2e) led 
to 80% protection against clade 2.3.2.1 strain. The protection conferred by Mw-HNM 
correlated with induction of IFN-γ, CD8+ T cytotoxic cells, and CD4+ T helper cells. 
Mw-adjuvanted HA + NP + M2e combination represents a promising vaccine candidate 
deserving further evaluation.
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inTrODUcTiOn
Highly pathogenic and rapidly evolving avian influenza virus, H5N1, remains a pandemic threat. 
Since the first human case of H5N1 infection in Hong Kong in 1997 (1), the number of human cases 
as of December 2015 increased to 844 across 16 countries with 53% mortality (2). Use of antiviral 
drugs for the treatment of influenza has limitations because of the emergence of drug-resistant strains 
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of H5N1 virus (3, 4). Evolution of H5N1 virus genetically and 
antigenically in 10 diversified clades (clade 0–9) (5) underscores 
the need for a broadly cross-reactive vaccine.
Currently available influenza vaccines mainly rely on HA 
antigens that do not offer protection against antigenically 
drifted strains (6). Therefore, the use of the conserved proteins 
of the virus such as nucleoprotein (NP) and M protein was con-
sidered for the generation of broadly reactive immune response 
and most desired “universal vaccine” (7, 8). Recombinant 
protein vaccines are regarded as safer alternatives in the 
pursuit of influenza vaccine development (9). However, lower 
immunogenicity of these proteins demands the use of potent 
adjuvants.
Among the protein antigens of influenza, HA is the major target 
for vaccine development because of the generation of virus neu-
tralizing antibodies (6) that have prophylactic role. Immunization 
with NP was shown to confer cross protection against influenza 
A heterosubtypic challenge through CD8+ T cell response (10). 
Non-neutralizing antibodies generated against NP were shown to 
help viral clearance through antibody-dependent cell cytotoxicity 
(ADCC) in mice (11). M2e, a 23aa peptide, an ectodomain of M2 
protein contains N terminal 9aa epitope (SLLTEVET), which is 
conserved among 99.3% of all the subtypes of influenza virus (12). 
To improve the poor immunogenicity of M2e, many researchers 
have used peptide carrier conjugates (13), multiple antigenic pep-
tides (14), and M2e fusion proteins (15). M2e-specific monoclonal 
antibodies have been shown to restrict viral growth in vitro (16) and 
also could protect mice after passive transfer (17). The protective 
role of M2e was shown to involve antibody-mediated inhibition 
of virus replication (18) and ADCC (19). M2 immunization was 
shown to provide cross protection against different influenza 
strains (20).
Following the introduction of H5N1 in India (21), we 
evaluated HA, NP, and M2e in different combinations using three 
adjuvants (22). Mw (heat-killed preparation of Mycobacterium 
indicus pranii) was identified for the first time as a promising 
adjuvant providing complete protection against homologous 
H5N1 challenge in mice. M. indicus pranii (previously known as 
Mw) (23) was developed as an immunomodulator for the treat-
ment of multibacillary lepromatous leprosy (24) and approved 
for human use by The Drugs Controller General of India and by 
US Food and Drug Administration. The immunomodulatory 
action of Mw mainly comprises of T cell response, activation of 
Th1 cell subtype, and enhanced secretion of IFN-γ and IL-2 (25). 
Mw-adjuvanted recombinant human chorionic gonadotropin 
vaccine elicited enhanced peak antibody titers and duration of 
antibody response (26).
In this study, we report inter-clade protection offered by 
Mw-adjuvanted formulation containing HA, NP, and M2e that 
was predominantly associated with cellular responses.
MaTerials anD MeThODs
ethics statement
This study was conducted as per the guidelines and approval of 
the Institutional Animal Ethics Committee (Approval No: IAEC/
HEP-14/NIV-54/2012 dated 03/08/2012). H5N1 virus challenge 
experiments were done at the BSL-3+ biosafety containment facil-
ity following the approval of the Institutional Biosafety Committee 
(Approval No: NIVIBSC/27.07.2012/4). The mortality aspects of 
the protocols were reviewed and approved by the Institutional 
Animal Ethics Committee. To minimize animal suffering and 
distress, isoflurane and ketamine–xylazine anesthetics were used 
during experimental procedures.
Viruses
H5N1-Navapur-A/chicken/India/33487/2006 (clade 2.2) and 
JC-2-1 NIVAN 1117307 (clade 2.3.2.1) influenza viruses isolated 
at National Institute of Virology were used for homologous and 
heterologous challenge, respectively. The clade 2.2 virus was 
used for the generation of recombinant proteins as described 
earlier (22).
immunogens
The HA gene was cloned in pFastBac1 and expressed in Spodoptera 
frugiperdii insect cells, and recombinant HA protein was purified 
using lentil lectin affinity chromatography (GE healthcare, USA). 
NP gene cloned in pET15b bacterial expression system was used 
to transform BL21 codon plus (RIL) cells. Recombinant NP 
protein was purified using Ni++ chelated resin (Invitrogen, USA). 
Synthetic M2e peptide, SLLTEVETPTRNEWECRCSDSSD, was 
obtained from INBIOS S.r.l, Italy.
adjuvants
Mw (5 × 109 cells/ml, heat-killed M. indicus pranii) was purchased 
from Cadila Pharmaceuticals India in the form of “Immuvac.” 
Mw formulations were prepared by mixing adjuvant and immu-
nogens (1:1 v/v ratio) to make a total of 100-µl dose per mouse 
containing 50 µl of Mw and 50 µl of immunogens.
Mice immunizations
Six to eight week old female inbred BALB/c mice were immu-
nized intramuscularly with 100 µl (50 µl per quadriceps muscle) 
of single or double doses of respective vaccine formulations 
given at 3-week intervals (Table  1; Figure  1). Mice were bled 
before immunization, 3 weeks post immunization, and 10 days 
post-second dose under isoflurane anesthesia. Control mice 
received PBS.
For immunophenotyping experiment, the immunized mice 
were sacrificed at 24  h/3  weeks post-dose-1 and 24  h/10  days 
post-dose-2. Harvested spleens were used for immunopheno-
typing by surface staining, cytokine estimation by cytometric 
bead array (CBA), and gene expression profiling by Taqman low 
density array (TLDA). Spleens from unimmunized mice were 
used for control.
serologic assays
For the detection and titration of IgG-anti-HA, NP, and M2e anti-
bodies, recombinant protein-based ELISA was used as described 
earlier (22, 27). IgG-subtype analysis was done as described 
previously (28).
TaBle 1 | hemagglutination inhibition (hi) and igg-anti-ha, nucleoprotein (nP), M2e titers in mice groups prior to virus challenge.
gr. no. immunogen Denotation 
used in 
study
anti-ha igg antibody 
titer (gM ± se)
anti-nP igg antibody  
titer (gM ± se)
anti-M2e igg 
antibody titer 
(gM ± se)
hi titer 
(gM ± se)
Formulations administered as two doses
1 10 µg HA + Mw Mw-HA 20,318 ± 4,267 – – 64 ± 13
2 10 µg NP + Mw Mw-NP – 58,813 ± 10,240 – –
3 10 µg HA + 10 µg NP + Mw Mw-HN 6,400 ± 0 102,400 ± 25,083 – 32 ± 6.7
4 10 µg HA + 10 μg NP + 50 μg M2e + Mw Mw-HNM 4,031 ± 1,067 270,235 ± 50,165 126 ± 33 4.3 ± 6
5 10 µg HA OP-HA 5,080 ± 1,067 – – 20 ± 0
6 10 µg NP OP-NP – 102,400 ± 0 – –
7 10 µg HA + 10 μg NP OP-HN 2,540 ± 1,600 51,200 ± 17,363 – 25 ± 6.7
8 10 µg HA + 10 μg NP + 50 μg M2e OP-HNM 2,540 ± 533 22,286 ± 7,011 504 ± 133 4.3 ± 6
Formulations administered as a single dose
9 10 µg HA + 10 µg NP + 50 µg M2e + Mw Mw-HNM 504 ± 133 155,209 ± 79,977 317 ± 67 –
10 10 µg HA + 10 μg NP + 50 μg M2e OP-HNM 1,600 ± 0 102,400 ± 155,402 252 ± 67 –
11 50 µg HA + 50 μg NP + 50 μg M2e + Mw 50-Mw-HNM 1,270 ± 267 3,200 ± 0 79 ± 17 –
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hemagglutination inhibition (hi) assay
The HI titers were measured on 10 days post-dose-2 as per the 
guidelines described in WHO manual (29) using receptor destroy-
ing enzyme (Denka Seiken UK Ltd., UK), 0.5% turkey erythro-
cytes, inactivated H5N1-Navapur-A/chicken/India/33487/2006 
virus (homologous HI titers), and JC-2-1 NIVAN 1117307 virus 
(heterologous HI titers).
immunophenotyping of splenocytes
Splenocytes were prepared using standard methods. One million 
cells were used for antibody labeling. Anti-mouse fluorochrome-
labeled antibodies used for different cell types were T cells: anti-
CD3-FITC (Clone 17A2), anti-CD4-APC/PE (Clone RM4-5), 
anti-CD8-APC (Clone 53-6.7); B cells: anti-CD19-APC-Cy7 
(Clone ID3), anti-CD45-FITC (Clone RA3-6B2); macrophages: 
anti-F4/80-FITC (Clone BM8), anti-CD105-APC (Clone 
MJ7/18); granulocytes: anti-Ly6G-FITC (Clone 1A8), anti-JAML-
PE (Clone 4E10); natural killer cells: anti-CD11b-FITC (Clone 
M1/70), anti-CD49b-APC (HMα2), anti-NKG2D-PE (CX5); and 
dendritic cells: anti-CD11c-APC (Clone HL3), anti-CD33D1-PE 
(Clone 33D1). Costimulatory and activation markers used were 
anti-CD69-PE/FITC (Clone H1.2F3), anti-MHCII-eFluor (Clone 
M5/114.15.2), anti-CD80-PE (Clone 16-10A1), anti-CD86-FITC 
(Clone GL1), anti-CD134-PE (Clone OX-86), and anti-CD137L-
PE (Clone TKS-1). These anti-mouse fluorochrome-labeled anti-
bodies were purchased from BD Pharmingen, USA/e-Bioscience, 
USA/Biolegend CA. A minimum of 10,000 events were acquired 
for every sample after gating splenocyte clusters. Acquisition of 
samples was carried out on BD FACS ARIA-II flow cytometer, 
and data were analyzed using BD FACS DIVA software (BD 
Biosciences, USA).
In Vitro stimulation of splenocytes
Splenocytes (one million) from mice groups at 10 days post-dose-2 
were cultured and stimulated with 1 µg HA + 1 μg NP + 5 μg M2e 
at 37°C for 4/24/72 h. The culture supernatants were tested for 
Th1 cytokines (IFN-γ, IL-2, and TNF) and Th2 cytokines (IL-4, 
IL-6, IL-10, and IL-5) by using CBA kit (BD Biosciences, USA) 
as described previously (30). As positive control, splenocytes 
stimulated with 2.5  µg/well concanavalin A (Sigma, USA) and 
as negative control, unstimulated cells were used. Cells collected 
after 4 and 24 h of stimulation were used for surface staining and 
gene expression analysis by TLDA.
TlDa
Frozen spleen samples were processed for total RNA extraction 
and gene expression analysis as described previously (31). cDNA 
prepared from 500 ng RNA was mixed with 2×PCR master mix 
(Life technologies, USA) and loaded on the Taqman mouse 
immune array panel card and run on 7900 Real-Time PCR System 
(Applied Biosystems, USA). cDNAs from the spleens of naive 
mice and the mock-immunized (PBS) control mice were used as 
calibrators. 18s gene was used as the endogenous control. Relative 
quantification (RQ) values obtained were used to calculate fold 
upregulation or downregulation. RQ values between 0.5 and 2 
were considered normal.
Virus challenge
Control and immunized mice with single dose or two doses of the 
respective formulations (n =  10/group) were challenged intra-
nasally with 50 µl of 100 LD50 homologous (H5N1-Navapur-A/
chicken/India/33487/2006) or heterologous (JC-2-1 NIVAN 
1117307) influenza virus under ketamine–xylazine anesthesia. 
Single-dose immunized mice were challenged post 3  weeks of 
immunization, while those receiving two doses were challenged 
on 10 days post-dose-2. Since the aim of this study was to assess 
the efficacy of different vaccine formulations against the chal-
lenge of H5N1 virus, euthanasia was not used till experimental 
endpoint [post infection day 14 (PID-14)] to find out if reversal 
of sickness occurs resulting into survival. Mice were monitored 
daily for 14 days for weight loss and mortality.
lung Viral load
Three mice per group were sacrificed 72 h post challenge (PID-3) 
and harvested lungs stored in RNA later at −80°C until tested. 
RNA was extracted from the lung homogenates using QIAmp 
FigUre 1 | antigen-specific serum igg antibody titers and isotype analysis. IgG anti-HA (a), anti-NP (B), and anti-M2e (c) antibody titers at 3 weeks 
post-dose-1 (for single-dose immunization) and 10 days post-dose-2 (for two-dose immunization) (prior to virus challenge) in mice immunized with different 
formulations and IgG1/IgG2a isotype analysis for HA-specific (D) and NP-specific (e) antibodies at these time points. Abbreviations: HA, hemagglutinin; NP, 
nucleoprotein; HN, HA + NP; HNM, HA + NP + M2e; HNM (SD), single-dose immunized HA + NP + M2e groups. Data are average of 10 mice per group. Error 
bars represent SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
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viral RNA mini kit (Qiagen, Valencia, CA, USA) according to 
the manufacturer’s instructions. Quantitation of viral RNA copy 
number was done by VLA Taqman wet assay real-time Influenza 
A/H5/H7 detection kit (Applied Biosystems, USA).
statistical analyses
Statistical analyses were performed using the SPSS 20 software 
(SPSS Inc., IL, USA). To compare antibody titers and proportions 
of immune cell types, Student’s t-test and ANOVA with Tukey’s 
post  hoc test were used, while Pearson correlation coefficients 
were determined by bivariate and partial correlation analyses. 
PCC values in the range 0.6–0.8 and >0.8 were considered to 
depict moderate and high correlation, respectively, at p < 0.05. 
Kaplan–Meier survival analysis was performed in GraphPad 
Prism software. The differences at p value <0.05 were considered 
significant for all the analyses.
resUlTs
We first determined antibody titers against each immunogen 
component of all the formulations studied followed by the protec-
tive efficacy against homologous virus challenge.
FigUre 2 | serum hi titers (geometric mean + se) prior to challenge 
(10 days post-dose-2). Abbreviations: HI, hemagglutination inhibition; HA, 
hemagglutinin; NP, nucleoprotein; HN, HA + NP; HNM, HA + NP + M2e.
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immunogenicity of Vaccine  
Formulations (elisa)
Table 1 and Figure 1 depict immunogen-specific IgG antibody 
titers (ELISA) and isotype analysis conducted prior to virus 
challenge. After first dose, all the immunized mice showed 100% 
seroconversion against HA, NP, and M2e.
Highest anti-HA-IgG titers were recorded with Mw-HA 
formulation (20,318 ± 4,267, Figure 1A), while the addition of 
other antigens, i.e., NP or NP + M2e led to a significant decrease 
(p < 0.05). No adjuvant effect was observed for the combination 
formulations. With a single dose at the same (p < 0.01) or higher 
(50 µg, p < 0.05) Mw-HNM concentration, the titers were lower 
than two doses of Mw-HNM and were concentration dependent 
(p < 0.05).
Response to NP was distinctly different (Figure 1B). The addi-
tion of Mw to NP lowered anti-NP antibody titers (p < 0.05), no 
change was recorded with Mw-HN formulations while the titers 
increased with Mw-HNM formulation (p <  0.05). Among the 
only-protein formulations, NP elicited significantly higher titers 
than HNM (p <  0.001). Anti-NP titers did not increase with 
the number of doses for Mw-HNM or HNM. In fact, higher 
immunogen concentration (50 µg) led to a significant decrease 
in the antibody titers (p <  0.001). Addition of Mw to HNM 
led to a significant reduction in anti-M2e IgG titers (p < 0.05) 
(Figure 1C). A significant lowering of anti-M2e titers was associ-
ated with increasing the number of doses or antigen concentra-
tion (p < 0.05).
The Th2 response exhibited by non-adjuvanted HA, HN, 
and HNM formulations was switched to a balanced Th1/Th2 
response in Mw-HA, Mw-HN, and the single dose-Mw-HNM/
HNM formulations (Figure 1D). As compared to a Th2 response 
with Mw-HNM, a single dose with fivefold higher antigen 
concentration led to a distinct Th1 response. Only NP, Mw-NP, 
Mw-HN, and Mw-HNM induced Th2 response, while a balanced 
Th1/Th2 profile was seen with HN, HNM, and Mw-adjuvanted 
single dose with higher antigen formulations (Figure 1E). Since 
anti-M2e-IgG titers were low in all the groups, isotype analysis 
was not done.
hi Titers
Addition of Mw to HA led to significantly higher HI titers 
(64 ± 13) (Figure 2). Similar to ELISA, addition of NM led to 
significant decrease in the Mw-HNM group (4.3 ± 6, p < 0.05). 
For HN and HNM formulations, no adjuvant effect was seen. 
When tested against the clade 2.3.2.1 virus, no HI activity was 
exhibited by these mice groups.
Protection of Mice against homologous 
and inter-clade Virus challenge and  
lung Viral load
The mice groups immunized with two doses of different for-
mulations were initially challenged with 100 LD50 homologous 
viruses. All the three adjuvanted formulations (Mw-HA, Mw-HN, 
and Mw-HNM) provided complete protection (Figure 3B). The 
weight loss was minimum in these groups (Figure 3A). Thus, the 
presence of HA was associated with complete protection. The 
protection conferred by the respective protein alone formulations 
was 83, 83, and 67%, respectively (Figure 3D). At 72 h post infec-
tion (PID-3), the control mice exhibited 3 × 108 RNA copies/ml 
lung suspension. Correlation of the reduction in lung viral load 
and 100% protection was seen with Mw-HA (14-fold, p < 0.001) 
and Mw-HN (29-fold, p <  0.001) groups, while protection in 
Mw-HNM group was associated with no reduction in the viral 
load (p > 0.05, Figure 4A).
Partial protection and considerable weight loss was observed 
with formulations containing only NP (Figures  3A–D). 
Interestingly, Mw-NP formulation leading to 21-fold reduction 
in the lung viral load provided only 17% protection (Figures 4A 
and 3B). A significant decline in viral load was recorded with 
HNM (29-fold, p <  0.05), while no reduction (p >  0.05) was 
noted with HA, NP, and HN formulations (Figure 4A). Clearly, 
protection did not correlate with the reduction in lung viral RNA 
load. With a single-dose HNM immunization, addition of the 
adjuvant led to higher protection (from 17 to 33%, Figure 3F) 
with appreciable weight loss (Figure 3E) and comparable lung 
viral load (Figure 4B).
We selected Mw-HA and Mw-HNM formulations providing 
100% protection against the homologous challenge for assessing 
efficacy against the inter-clade challenge. Irrespective of the 
adjuvant, HA led to 50% protection (Figure 3H), while 100% pro-
tection was achieved by the addition of the conserved antigens; 
only HNM conferred 33% survival. Importantly, a single dose 
with higher antigen concentration could provide 80% protection. 
Weight loss was inversely proportional to the survival rate for all 
the groups (Table S1 in Supplementary Material, Figure 3G). No 
reduction in viral load was observed for any of the groups studied 
(p > 0.05) (Figure 4C).
correlation of Protection with  
Parameters studied
We further attempted to understand the correlation of observed 
protection and different parameters studied. Bivariate correlation 
analysis documented highest positive correlation with anti-
HA-IgG2a (PCC =  0.918, p =  0.001) followed by anti-HA-IgG 
FigUre 3 | Morbidity and survival kinetics post challenge. Immunized and control mice were inoculated intranasally with 100LD50 homologous/heterologous 
H5N1 virus. The controls received PBS (n = 10/group). The groups challenged with homologous virus include Mw formulations (a,B), only-protein formulations 
(c,D), and single-dose immunized mice groups (e,F). (g,h) present mice groups immunized with single- and double-dose receiving challenge with heterologous 
virus. Abbreviation: HA, hemagglutinin; NP, Nucleoprotein; HN, HA + NP; HNM, HA + NP + M2e; (SD) indicate single-dose immunized groups. % weight loss 
indicates mean of six mice ± SE.
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(PCC  =  0.892, p  =  0.003), anti-HA-IgG1 (PCC  =  0.824, 
p = 0.012), and HI titers (PCC = 0.797, p = 0.018). Partial correla-
tion analysis identified anti-HA IgG2a (PCC = 0.790, p = 0.034), 
i.e., Th1 response as the only marker correlating with protection. 
Importantly, HI titers showed high correlation with anti-HA-
IgG (PCC =  0.867, p =  0.005), anti-HA IgG1 (PCC =  0.827, 
p = 0.011), and anti-HA IgG2a (PCC = 0.840, p = 0.009) titers 
noted in ELISA.
FigUre 4 | lung viral load. Viral RNA copies per milliliter in the lung suspension of mice at 72 h post infection in (a) homologous challenge two-dose 
immunization, (B) homologous challenge single-dose immunization, and (c) heterologous challenge groups. Abbreviations: HA, hemagglutinin; NP, nucleoprotein; 
HN, HA + NP; HNM, HA + NP + M2e. **p < 0.01 and ***p < 0.001.
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Based on the above results, Mw-HNM was identified as the 
most efficacious formulation and investigated further.
immunophenotyping of splenocytes  
from immunized Mice
As a first step, we determined the proportion of different 
immune cell types in the spleens of the immunized mice. For 
this, a few cell types playing crucial role in the generation of 
innate (macrophages, granulocytes, DCs, and NK cells) and 
adaptive (T helper, T cytotoxic, and B cells) immune response 
were studied. Figure S1 in Supplementary Material provides 
gating strategy.
24 h Post-Dose-1
As compared to the PBS controls, involvement of dendritic cells 
was seen in both the groups (Figure 5G), while macrophages were 
restricted to the HNM-alone group (p < 0.01, Figure 5D). Both 
the groups exhibited higher levels of B cells (p < 0.05, Figure 5C), 
while T helper cells reduced (p < 0.05, Figure 5A).
Comparison of Mw-HNM and HNM groups showed a 
significant increase in the levels of macrophages (p  <  0.05, 
Figure 5D) in the HNM group, while the proportion of dendritic 
cells was comparable (Figure 5G). The Mw-HNM formulation 
was characterized by the higher proportion of both T helper and 
T cytotoxic cells (p < 0.05, Figures 5A,B), whereas lower levels of 
B cells (p < 0.05, Figure 5C) than the HNM category.
3 Weeks Post-Dose-1
When compared to the controls, involvement of NK cells was 
apparent only in the Mw-HNM group (Figure 5E). In both the 
groups, proportion of B cells was significantly higher (p < 0.05, 
Figure 5C) than PBS control but was comparable in between.
24 h Post-Dose-2
Following second dose of the respective formulations, the levels 
of T cytotoxic cells, B cells, and macrophages were higher in 
both the groups, when compared to the controls (p  <  0.05, 
Figures  5B–D), while an increase in granulocytes (p <  0.05, 
Figure 5F) and dendritic cells (CD33D1+, p < 0.05, Figure 5H) 
was recorded in Mw-HNM.
When the two formulations were compared, raised levels of 
dendritic cells in the adjuvanted category (p < 0.05, Figure 5H) 
were recorded.
10 Days Post-Dose-2
At this time point (just prior to challenge), B cells (p <  0.01, 
Figure  5C) and the effector cells for adaptive immunity, i.e., 
activated T helper (p < 0.001), activated T cytotoxic (p < 0.001, 
data not shown) were raised in the Mw-HNM group.
FigUre 5 | enumeration of immune cells by surface staining at different time points post immunization. Splenocytes from Mw-HMN and HNM-alone 
immunized mice were used at for immunophenotyping at 24 h post-dose-1 (TP1), 3 weeks post-dose-1 (TP2), 24 h post-dose-2 (TP3), and 10 days post-dose-2 
(TP4). (a) T helper cells, (B) T cytotoxic cells, (c) B cells, (D) macrophages, (e) NK cells, (F) granulocytes, and (g,h) DCs. Values represent mean % of gated 
splenocytes ± SD. Abbreviation: HNM, HA + NP + M2e. *p < 0.05, **p < 0.01, and ***p < 0.001.
8
Ingle et al. Efficacy of Mw-Adjuvanted H5N1 Vaccine
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 674
immunophenotyping of In Vitro stimulated 
splenocytes from the immunized Mice
At 4 H Post-Stimulation
T helper cells, T cytotoxic cells with costimulatory mol-
ecule (CD8+CD86+), activated B cells (CD19+CD69+, 
CD19+MHCII+CD69+), and activated macrophages (F4/80+ 
MHCII+CD69+) increased in Mw-HNM group (p  <  0.05) 
(Figures  6A,D), while the levels of DCs (CD11c+, p <  0.05), 
activated DCs (CD11c+CD69+, p < 0.05), and NK cells (CD11b+ 
CD49b+, p < 0.01) were reduced (Figures 6B–D). No significant 
increase in any cell type and decreased levels (p < 0.05) of activated 
T cells (CD3+CD69+), T cytotoxic cells, B cells (CD19+CD80+), 
DCs (CD11c+), and NK cells (CD11b+CD49b+) were noted for 
HNM (Figures 6A–D).
At 24 H Post-Stimulation
Continued raised proportion of T helper cells (p < 0.001) or acti-
vated B cells (CD19+MHCII+CD69+, p < 0.01) (Figures 6G,E) and 
increase in the levels of activated T cells (CD3+CD69+, p < 0.05) 
was recorded in the Mw-HNM group (Figure 6E), whereas the 
proportion of NK cells decreased (p < 0.05) (Figure 6F). The only-
protein group showed a significant rise in the levels of T helper 
cells (p < 0.05) and activated T cytotoxic cells (CD3+CD8+CD69+, 
p  <  0.05) (Figures  6G,F), while activated T  helper cells 
FigUre 6 | enumeration of immune cells by surface staining post antigen stimulation. Splenocytes from Mw-HMN and HNM-alone immunized mice were 
stimulated with HNM and were used for immunophenotyping at 4 h post-stimulation (a–D) and 24 h post-stimulation (e–g). Abbreviations: US, unstimulated 
groups; S, stimulated groups; Mw, Mw-HNM groups; OP, only-protein groups (HNM); HNM, HA + NP + M2e. Values represent mean % of gated splenocytes ± SD. 
*p < 0.05, **p < 0.01, and ***p < 0.001.
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(CD4+CD69+, p < 0.05) and B cells (CD19+MHCII+, p < 0.01) 
decreased (Figures 6F,E).
cytokine estimation and gene expression
Culture supernatants of antigen-stimulated splenocytes were 
used for cytokine estimation. No cytokines were detected at 4 
and 24 h post-stimulation in Mw-HNM and HNM groups, while 
higher levels of IFN-γ (689.5 and 165.8 pg/ml), TNF (260.3 and 
210.1  pg/ml), and IL-6 (235.3 and 100.5  pg/ml) were detected 
at 72  h. A marginal (1.8  pg/ml) and no increase in IL-2 levels 
was noted in Mw-HNM and only-protein groups, respectively. 
Mw-induced induction of the signature Th1 cytokine, IFN-γ, 
was evident. None of the Th2 cytokines tested (IL-4, IL-5) were 
detected in both Mw-HNM and HNM groups.
Gene expression analysis was done using splenocytes from 
the immunized mice (1) prior to virus challenge (unstimulated 
splenocytes) and (2) in  vitro cultured and antigen-stimulated 
splenocytes (4 and 24  h). As evident from the heatmap 
(Figure  7), stimulated splenocytes from the HNM group 
formed a distinct cluster, while the unstimulated splenocytes 
from Mw-HNM and HNM-alone groups and stimulated sple-
nocytes from the Mw-HNM group formed two branches of the 
FigUre 7 | heatmap of immune response genes from spleens of 
immunized mice with Mw-hnM or hnM. Unstimulated spenocytes 
collected prior to virus challenge and stimulated with HNM for 4/24 h were 
studied. The color code: green (downregulation), black (normal), red 
(upregulation), and gray (unavailability of valid value) of the corresponding 
gene. Abbreviation: HNM, HA + NP + M2e.
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second cluster. Table S2 in Supplementary Material presents 
modulation of mRNA levels of the immune response genes at 
different time points. Overall, Th1/Th2 and proinflammatory 
cytokine genes were upregulated in Mw-HNM and down-
regulated in HNM-alone groups. CD19 was upregulated in the 
unstimulated Mw-HNM and HNM groups, while the other 
immune cell surface marker genes were expressed normally. 
At 4  h post-stimulation, CD19, CD3, CD4, CD8, CD40, and 
CD80 genes were downregulated in the HNM group. Of these, 
CD19, CD40, and CD80 genes remained downregulated at 24 h 
post-stimulation. The mRNA levels of CD19, CD4, CD8, and 
CD80 were upregulated at both time points in the Mw-HNM 
group. Of note, FACS (protein) and TLDA (gene) correlated 
well (Figures 5–7).
DiscUssiOn
Due to ever-changing influenza virus genome and a potential 
threat of a pandemic with H5N1 virus causing high mortality, 
there is a definite need for a broad-spectrum vaccine that can 
be produced rapidly in large quantities and economically viable. 
HA has been the obligatory immunogen for influenza vaccines, 
while the two internal proteins, NP and M2, are being evaluated 
as universal, conserved antigens. Previously, we identified for 
the first time, utility of Mw adjuvant in providing protection 
against homologous H5N1 challenge in mice when immunized 
with several combinations of recombinant HA, NP, and M2e 
(22). The current study extends this observation to cross-clade 
challenge and attempts to understand preliminary immunologic 
mechanism(s) of the adjuvant action. The 5-µg concentration of 
recombinant antigens was increased to 10  µg and that of M2e 
peptide to 50 µg per dose.
The protection against 100LD50 homologous challenge varied 
from 17 to 100% when different formulations were used. The 
protective role of HA was evident by the minimum weight loss 
and 100% protection offered by two doses of all the adjuvanted, 
HA-containing formulations (Mw-HA, Mw-HN, and Mw-HNM). 
On the contrary, adjuvanted NP provided 17% protection, while 
M2e alone or in combination with NP was not tried. MVA vec-
tors expressing H5N1-NP alone or coexpressed with H5N1-HA 
stem protected 50 and 100% mice, respectively, against 42 LD50 
challenge of homologous H5N1 virus (32). The difference in the 
challenge dose may have resulted in the lower NP alone-induced 
protection noted in our study.
The high immunogenicity of recombinant HA produced 
in baculovirus system was evident by 83% survival of mice 
immunized with HA alone. Though the conserved NP and 
M2e were added to aid this protective immune response, 
addition of NP did not improve the survival rate (83%), while 
HA + NP + M2e combination led to a reduction to 67%. It is 
interesting to note that the addition of NP or NP +  M2e to 
Mw-HA resulted in a gradual decline in both anti-HA-IgG and 
HI antibodies (Table 1; Figures 1 and 2). Clearly, the protec-
tion was not anti-HA antibody-dependent. An increasing 
trend was seen for anti-NP antibodies, Mw-HNM inducing 
highest anti-NP titers (p < 0.05). M2e elicited uniformly low 
antibody titers. Taken together, the results suggest non-HA-
antibody-associated protection and/or role of NP/M2e in 
offering protection.
The most promising finding of this study is complete pro-
tection of mice immunized with two doses of Mw-HNM (2.2 
clade) against intranasal challenge of 100LD50 of the 2.3.2.1 
clade strain. Protection with HNM-alone was 33% documenting 
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pronounced adjuvant effect of Mw. We would like to point out 
here that based on high inter-cladal antigenic differences, Bhat 
et  al. postulated unsuitability of clade 2.2 vaccine in provid-
ing protection against clade 2.3.2.1 virus (33). Importantly, in 
accordance with the documentation of suitability of clade 2.2 
vaccine as a good priming vaccine for prime-boost regimen in 
a pre-pandemic situation (34), Mw-HNM formulation appears 
worth considering.
Though not strain-matched, both HA and Mw-HA yielded 
50% protection that may be attributed to the generation of 
antibodies against conserved epitopes of globular HA and/or 
broadly reactive HA-stem epitopes, high affinity and avidity of 
the antibodies generated, and/or cellular response to HA. Also, 
80% protection offered by a single dose of adjuvanted 50  µg 
immunogen preparation is indeed promising and needs to be 
explored further.
Though both humoral and cell-mediated immune responses 
are crucial for protection/recovery in influenza infections, 
efficacy of the conventional influenza vaccines is judged by HI 
titers. HI titer of ≥40 is considered protective for the seasonal 
influenza vaccines. However, lack of universal compliance is 
recorded (35). HI-independent protection observed by us con-
firms earlier reports (36–39) and suggests possible role of other 
immune mechanisms. NP alone with or without Mw provided 
17% protection suggesting partial protection in the absence of 
anti-HA immune response.
A recent study showed that the incorporation of NP of 
H5N1 virus into HA-NA-M1/M2-VLPs enhanced the immune 
response and protection against heterologous H5N1 strains that 
correlated with the generation of high level anti-NP antibodies. 
In contrast, VLPs without NP provided 50% protection (40). 
We have used Mw-adjuvanted mixture of HA, NP, and M2e 
and obtained similar results and are tempted to conclude that 
Mw-HNM, simpler to prepare, may be an attractive alternative 
to the VLPs.
Protection against heterotypic strains was earlier shown 
to be dependent on the preexisting, virus-specific CD4+ and 
CD8+ T cells that target the conserved internal proteins of 
the virus (41, 42). Accordingly, adjuvants enhancing cellular 
immune responses are of special relevance for H5N1, and 
Mw is a strong T cell-inducer. We detected antigen-specific 
cellular responses with unadjuvanted HNM formulation that 
were adequately enhanced by the adjuvant leading to 100% 
protection. However, since we did not investigate NP alone, 
M2e alone, or NP–M2e combination formulations for antigen-
specific cellular responses, we are not able to differentiate 
cellular responses contributed by the respective antigens singly 
or in combination.
Immunophenotyping of spleens from the immunized mice 
revealed that high immunogenicity of the Mw-HNM and HNM 
formulations correlated with an early (24  h post-dose-1) and 
significantly increased recruitment of DCs, the most efficient 
antigen-presenting cells, CD8+ cells, and B cells. Mw aided the 
immune response by a further increase in the CD8+ T cells and 
sustained CD4+/CD8+ T and B cells at the time of virus chal-
lenge. Importantly, the HNM-alone-induced lowering of T helper 
cells that are indispensable for the development of cytotoxic and 
antibody responses and was compensated by Mw. Protection 
against lethal challenge with H5N1 was shown to be associated 
with high CD4+ T cell responses against whole-virus antigen but 
not against recombinant H5 HA, indicating that protection was 
due to T cell responses against NP but not HA (32). Overall, there 
is a definite need to establish appropriate correlates of protection 
for H5N1 virus.
We did not examine specific immune cells for the effect of 
antigen stimulation. However, restimulation of cultured sple-
nocytes with HNM revealed clear advantage of the adjuvant 
as evidenced by a rapid increase (4 h post-stimulation) in the 
frequencies of CD4+ T cells, CD8+ cells with costimulatory 
molecule (CD8+CD86+), activated B cells, and activated mac-
rophages. An inverse relationship between preexisting CD8+ 
T cells, and disease severity was shown during the pandemic 
of 2009 (43). Association of the robust NP-specific CD8+ T 
cell responses with increased protection against lethal H5N1 
challenge indicates possible role of NP (32) and confirms 
previous findings in humans that CD8+ T cell responses 
against conserved influenza epitopes correlate with protection 
against influenza (43). M2e alone is a very poor immunogen 
and needs carrier proteins/adjuvants for the improvement of 
immunogenicity (44). Several studies have shown superior 
immune response when M2e was used with other viral antigens 
and adjuvants (45).
Immune response gene expression analysis showed a concom-
itant increase in the expression of immune cell surface proteins 
and higher mRNA levels of CD3, CD4, CD8, CD19, CD40, CD80, 
CD86 genes in the Mw-HNM and substantial downregulation 
of these genes in HNM category suggestive of modulation at 
translational level as well.
Correlation of anti-HA IgG2a with the observed protec-
tion emphasizes the usefulness of Mw adjuvant in modulating 
immune response to Th1 type that is beneficial for protection that 
was further confirmed by the induction of influenza-specific Th1 
cytokines (IFN-γ, TNF, and IL-2) and undetectable levels of Th2 
cytokines (IL-4 and IL-10) in the Mw-HNM group. An increase 
in IFN-γ and IL-2 cytokines and absence of IL-4 in the stimulated 
T cells (25) and production of high levels of TNF-α (46) have 
been reported with Mw adjuvant alone in mice. We did observe 
a correlation of gene and protein expression with Th1 and not 
Th2 cytokines.
Taken together, our results clearly point out that 2.2 clade-
based HNM when adjuvanted with Mw is a promising H5N1 
vaccine candidate, and the protection is primarily associated 
with cellular immune responses. Importantly, Mw is approved 
by FDA for human use in US and India. A single dose of 50 µg 
could provide 80% protection qualifying the formulation as a pre-
pandemic vaccine. Mw-HNM deserves further experimentations 
toward a usable pandemic vaccine.
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